Arianna Ferrari Christopher Coenen Armin Grunwald Arnold Sauter ...

Lanone S., Boczkowski J. (2006): Biomedical applications and potential health
risks of nanomaterials: molecular mechanisms,
Current Molecular Medicine 6(6): 651–63.
Lanzerath D. (2008): Die neuere Philosophie der Gesundheit. Von der Norma-
tivität des Krankheitsbegriffs zur Medikalisierung der Gesellschaft. In: Schäfer
D. et al. Gesundheitskonzepte im Wandel. Geschichte, Ethik und Gesellschaft.
Stuttgart: Franz Steiner Verlag: 203–214.
Lariviere W.R., Chesler E.J., Mogil J.S. (2001): Transgenic studies of pain and
analgesia: mutation or background genotype?, The Journal of pharmacology
and experimental therapeutics 297(2): 467–473.
Latour B. (1989): Science in Action: How to follow scientists and engineers
through society. Cambridge: Harvard University Press, Cambridge.
Latour B. (1995) Wir sind nie modern gewesen: Versuch einer symmetrischen
Anthropologie. Akademie Verlag: Berlin.
Lazaris A., Arcidiacono S., Huang Y. et al. (2002): Spider Silk Fibers Spun
from Soluble Recombinant Silk Produced in Mammalian Cell,
Science 18 295: 472–476.
Le Bas-Bernardet S., Anegon I., Blancho G. (2008): Progress and prospects:
genetic engineering in xenotransplantation, Gene Therapy 15(18): 1247–56.
Le Ker H. (2008): Gendoping. Die Erbgutschleicher kommen, Spiegel Online
04.08.2008, http://www.spiegel.de/wissenschaft/mensch/0,1518,569346,00.html
(zuletzt aufgerufen am 23/07/10).
Lebedev M.A., Nicolelis M.A. (2006): Brain-machine interfaces: past, present
and future, Trends in Neuroscience 29(9): 536–546.
Lee B. et al. (2005): Dogs cloned from adult somatic cells, Nature 436: 641.
Lee Y.S., Silva A.J. (2009) The molecular and cellular biology of enhanced
cognition, Nature Revue of Neuroscience 10(2):126–40.
Lehrer J. (2009): Neuroscience: Small, furry ... and smart,
Nature 461(7266): 862–864.
Lenk C. (2002): Therapie und Enhancement. Ziele und Grenzen der modernen
Medizin. Lit Verlag: Münster.
Leo S. et al. (2008): Differences in nociceptive behavioral performance
between C57BL/6J, 129S6/SvEv, B6 129 F1 and NMRI mice,
Behavioural Brain Research 190(2): 233–242.
Leroy M., Pire G., Baise E., Desmecht D. (2006): Expression of the interferon-
alpha/beta-inducible bovine Mx1 dynamin interferes with replication of rabies
virus, Neurobiological Discovery 21: 515–521.
Liang X.J., Chen C., Zhao Y. et al. (2008): Biopharmaceutics and therapeutic
potential of engineered nanomaterials, Current Drug Metabolism 9(8): 697–709.
Liggett S.B. (2004): Genetically modified mouse models for pharmacogenomic
research, Nature Review Genetics 5, September 2004: 657–662.
Lindpaintner K. (2002): Pharmakogenomik: Paradigmenwechsel in der
Therapie? Verein «Forschung fur Leben» November 2002, Nr. 63,
http://www.forschung-leben.ch/download/BioFokus63_lang.pdf
(zuletzt aufgerufen am 23/07/10).
Loi P., Galli C., Ptak G. (2007): Cloning of endangered mammalian species:
any progress?, Trends in Biotechnology 25(5): 195–200.
London B.M., Jordan L.R, Jackson C.R., Miller L.E. (2008): Electrical stimu-
lation of the proprioceptive cortex (area 3a) used to instruct a behaving monkey,
IEEE Trans Neural Syst Rehabil Engineering 16(1): 32–36.
Long, K.D., Kennedy G., Balaban E. (2001): Transferring an inborn auditory
perceptual predisposition with interspecies brain transplants, Protocols of the
National Academy of Science USA 98: 5862–5867.
LTC (2009a): DIABECELL ® . Life-changing cellular therapy for Type
1 diabetes, http://www.lctglobal.com/lct-diabecell-diabetes-treatment.
php#clinicalTrials (zuletzt aufgerufen am 23/07/10).
200 Animal Enhancement | Beiträge zur Ethik und Biotechnologie Animal Enhancement | Beiträge zur Ethik und Biotechnologie
201